Lung cancer treatment: Deguelin playing essential role for lung cancer

Sep 4
09:18

2009

Koay Lye Chin

Koay Lye Chin

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

It talk about deguelin playing essential role for lung cancer

mediaimage

In year 2002,Lung cancer treatment: Deguelin playing essential role for lung cancer Articles scientist found out that Deguelin was being able to inhibit the growth of lung cancer cell and other precancerous.  The findings also published in US Journal of the National Cancer Institute. Deguelin was widely used as an insecticide in South American and African.Degueline is a chemopreventive activities and be able to reduce lung cancer tumor incidence and other form of cancer like colon.

Deguelin has been very effective to inhibit the growth of malignant particular for lung cancer. It as an inhibitor of AKT or protein kinase B, is it has recognized as a molecule that spread over of tumor cell, Degueline contain no toxic effect cancer cell. However, if patient overdose of it may cause nerves, lung and heart disease, so that reasonable dose should be taken even is a naturally substance.  It considered another form of lung cancer treatment.

Besides that, deguelin was being found out it be able to prevent lung cancer from a smoking. Deguelin as a chemical make huge reduction of the lung cancer tumors.  Scientist recommended that each day take twice with 4mg/kg is a less chance of developing lung cancer from whom smoking or non smoking but high exposure in passive smoking area. Deguelin may consideredlung cancer treatmentfor early stage of lung cancer, scientist found that degueline inhibiting AKT activities with 10 to 100 Mm where small molecule originally from natural substance where marked reduction malignant

"The results of our study provide evidence for the first time that Akt is essential in the growth of precancerous human bronchial epithelial cell line, and that deguelin can be a potential chemopreventive agent against lung cancer," according to Ho-Young Lee, Ph.D., lead investigator of the study, which was conducted by researchers at UT M.D. Anderson Cancer Center.